¼¼°èÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Peripheral Artery Disease Market Size Study, by Product Type (Devices, Drugs), by End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers), and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1517416
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2024³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 200 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀº 2023³â ¾à 45¾ï ´Þ·¯ ±Ô¸ð·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 7.7% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸»Ãʵ¿¸ÆÁúȯ(PAD)Àº ÁÖ·Î ´Ù¸®ÀÇ µ¿¸ÆÀÌ Á¼¾ÆÁö°Å³ª ¸·Çô¼ ÇöóÅ©¶ó°í ºÒ¸®´Â Áö¹æ Ä§Âø¹°ÀÌ ÃàÀûµÇ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. PAD´Â °ü»ó µ¿¸Æ Áúȯ, ½ÉÀå ¸¶ºñ, ³úÁ¹Áß°ú °°Àº ´Ù¸¥ ½ÉÇ÷°ü Áúȯ°ú °ü·ÃÀÌ ÀÖÀ¸¸ç Èí¿¬, ´ç´¢º´, °íÇ÷¾Ð, °í ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡¿Í °°Àº °øÅëµÈ À§Çè ¿äÀÎÀ» °øÀ¯Çϸç, ƯÈ÷ ¿îµ¿ Áß¿¡ ´Ù¸® ÅëÁõ, °æ·Ã, ¾àÁ¡ ¹× ¹«°¨°¢°ú °°Àº Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. PADÀÇ Ä¡·á´Â Áõ»ó °ü¸®, ÇÕº´Áõ ¿¹¹æ, Ç÷¾×¼øÈ¯ °³¼±¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù.
¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ¼ºÀåÀº ÀÌ ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ Å©°Ô °ßÀεǰí ÀÖ½À´Ï´Ù. ±¹¸³ÀÇÇеµ¼°üÀÇ 2023³â º¸°í¼¿¡ µû¸£¸é, PAD´Â Àü ¼¼°èÀûÀ¸·Î 2¾ï ¸í ÀÌ»óÀÇ ¼ºÀÎÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ Àúħ½ÀÀû ½Ã¼úÀÇ Ã¤ÅÃÀÌ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀåÀº PAD À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ÀÇ ±Þ°ÝÇÑ Áõ°¡, PAD Ä¡·á ±â±âÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹½ÉÀåÇÐȸ(American College of Cardiology)´Â 2023³â Àü ¼¼°èÀûÀ¸·Î ¾à 2¾ï ¸íÀÌ PAD¸¦ ¾Î°í ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ°¡´Â ºñ¸¸°ú ´ç´¢º´ ºñÀ² Áõ°¡, Èí¿¬ ¹× ÁÂ½Ä »ýȰ½À°ü°ú °°Àº »ýȰ½À°ü °ü·Ã À§Çè¿äÀο¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ¶§¹®ÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é, 2022³â¿¡´Â Àü ¼¼°è 8¸í Áß 1¸íÀÌ ºñ¸¸°ú °øÁ¸ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, PAD ¹ßº´·üÀº ´õ¿í ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ³ôÀº Ãʱâ ÅõÀÚ ºñ¿ë°ú ½ÅÈï±¹ ½ÃÀå¿¡¼ÀÇ Á¦ÇÑµÈ Á¢±Ù¼ºÀº 2024-2032³â ÃßÁ¤ ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä °úÁ¦ÀÔ´Ï´Ù. Àü ¼¼°èÀûÀÎ ºñ¸¸°ú ´ç´¢º´ÀÇ È®»êÀº PADÀÇ ¹ßº´ ¹× ÁøÇà°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ Àֱ⠶§¹®¿¡ PAD ¹ßº´·ü Áõ°¡¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. Èí¿¬°ú ¿îµ¿ ºÎÁ·°ú °°Àº °Ç°¿¡ ÇØ·Î¿î »ýȰ ½À°üÀº À§ÇèÀ» ´õ¿í ¾ÇȽÃ۰í Àü ¼¼°èÀûÀ¸·Î PADÀÇ ºÎ´ãÀ» Áõ°¡½Ã۰í ÀÖÀ¸¸ç, PAD ¹ßº´·ü Áõ°¡´Â È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁ® ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àα¸ °í·ÉÈ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Institute of Health Metrics and EvaluationÀÇ 2023³â ³í¹®¿¡ µû¸£¸é, PADÀÇ Àü ¼¼°è À¯º´·üÀº ³ë³âÃþÀϼö·Ï ³ôÀ¸¸ç, °í·ÉȰ¡ ÁøÇàµÊ¿¡ µû¶ó PADÀÇ ¹ßº´ À§ÇèÀÌ Å©°Ô Áõ°¡ÇÕ´Ï´Ù. ³ëÈ´Â µ¿¸Æ °æÈ, ³»ÇÇ ±â´É Àå¾Ö, Á×»ó µ¿¸Æ °æÈÁõ ÇöóÅ© ÃàÀû°ú °°Àº Ç÷°üÀÇ ±¸Á¶Àû ¹× ±â´ÉÀû º¯È¸¦ À¯¹ßÇϸç, ÀÌ ¸ðµç °ÍÀÌ PADÀÇ ¹ßº´°ú ÁøÇàÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.
³ë³âÃþ¿¡¼ PADÀÇ À¯º´·ü Áõ°¡´Â ³ëÀÎÀÇ Æ¯¼º¿¡ ¸Â´Â È¿°úÀûÀÎ °ü¸® Àü·«°ú ÀÇ·á °³ÀÔÀÌ ½Ã±ÞÈ÷ ÇÊ¿äÇÏ´Ù´Â Á¡À» °Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áÁø°ú Á¤Ã¥ ÀÔ¾ÈÀÚµéÀº ³ëÀÎ PADÀÇ ¿µÇâÀ» ÃÖ¼ÒÈÇϱâ À§ÇØ Á¶±â ¹ß°ß, Á¾ÇÕÀûÀÎ À§Çè ¿äÀÎ °ü¸®, Àû½Ã¿¡ °³ÀÔÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â °ÍÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀû ¼ö¼úÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº ±âÁ¸ÀÇ °³º¹ ¼ö¼ú¿¡ ´ëÇÑ ´ú ħ½ÀÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÏ¿© ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀ̰í, ÀÔ¿ø ±â°£À» ´ÜÃàÇϸç, ȸº¹ ½Ã°£À» ´ÜÃàÇϰí, °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. Á¤±³ÇÑ Ä«Å×ÅÍ ±â¹Ý Àåºñ¿Í ±â¼úÀÇ ¹ß´Þ·Î PAD¿¡ ´ëÇÑ ÃÖ¼Òħ½ÀÀû Ä¡·á ¿É¼ÇÀº ´õ¿í ´Ù¾çÇØÁö°í ÀÖ½À´Ï´Ù. ÷´Ü Ç÷°ü¼ºÇü¼ú dz¼±, ¾à¹° ÄÚÆÃ Ç³¼±, µ¿¸ÆÀýÁ¦¼ú ÀåÄ¡, ¸»ÃÊÇ÷°ü ÁßÀç½Ã¼ú Àü¿ëÀ¸·Î ¼³°èµÈ ½ºÅÙÆ® µî ´Ù¾çÇÑ Ä¡·á¹ýÀÌ °³¹ßµÇ¾î ´õ ³ôÀº À¯¿¬¼º, Àü´Þ¼º ¹× È¿°ú¸¦ Á¦°øÇÕ´Ï´Ù.
EV Àü¼Û ½Ã½ºÅÛ ¼¼°è ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â 2023³â ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â ÀÇ·á ÀÎÇÁ¶ó°¡ ¹ß´ÞÇϰí ÁÖ¿ä ÁÖ¿ä ±â¾÷µéÀÌ °·ÂÇÑ ÀÔÁö¸¦ ±¸ÃàÇϰí ÀÖÀ¸¸ç, PAD À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³ëÀÎ Àα¸ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ÁÖ¿ä ¿ä¾à
- ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦2Àå ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ »çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ȯ°æ
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼ú Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó³â
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç° À¯Çüº°, 2022³â-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
Á¦6Àå ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022³â-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
- º´¿ø
- Àü¹® Ŭ¸®´Ð
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
Á¦7Àå ¼¼°ÔÀÇ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022³â-2032³â
- ºÏ¹Ì ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ¹Ì±¹ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ij³ª´Ù ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- À¯·´ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ¿µ±¹ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- µ¶ÀÏ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ÇÁ¶û½º ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ½ºÆäÀÎ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ÀÌÅ»¸®¾Æ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ±âŸ À¯·´ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾ç ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- Áß±¹ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- Àεµ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ÀϺ» ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- È£ÁÖ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- Çѱ¹ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ¶óƾ¾Æ¸Þ¸®Ä« ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ºê¶óÁú ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ¸ß½ÃÄÚ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- »ç¿ìµð¾Æ¶óºñ¾Æ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹ ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸»Ãʵ¿¸ÆÁúȯ ½ÃÀå
Á¦8Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Philips N.V.
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Braun Melsungen AG
- Medtronic
- Bayer AG
- Boston Scientific Corporation
- Becton Dickinson and Company
- Terumo Medical Corporation
- Biotronik
- Cardinal Health
- Abbott
- Johnson & Johnson
- Cook Medical
- AngioDynamics
- Endologix
- Shockwave Medical
Á¦9Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
LSH
¿µ¹® ¸ñÂ÷
Global Peripheral Artery Disease Market is valued at approximately USD 4.5 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.7% over the forecast period 2024-2032. Peripheral artery disease (PAD) is characterized by the narrowing or blockage of the arteries, primarily in the legs, due to the buildup of fatty deposits called plaque. This condition restricts blood flow to the limbs, causing symptoms such as leg pain, cramping, weakness, and numbness, particularly during physical activity. PAD is linked to other cardiovascular conditions like coronary artery disease, heart attack, and stroke, sharing common risk factors such as smoking, diabetes, high blood pressure, and high cholesterol levels. The treatment for PAD focuses on symptom management, complication prevention, and improved circulation.
The market growth for peripheral artery disease is significantly driven by the rising prevalence of the condition. According to a 2023 report by the National Library of Medicine, PAD affects over 200 million adults globally. Additionally, the adoption of minimally invasive procedures is expected to substantially contribute to market growth. The peripheral artery disease market is poised for substantial expansion due to the increase in PAD prevalence, the surge in the geriatric population, and technological advancements in PAD treatment devices. The American College of Cardiology estimated that around 200 million people worldwide were affected by PAD in 2023, a rise attributed to factors such as increasing obesity and diabetes rates, as well as lifestyle-related risk factors like smoking and sedentary behaviors. The World Health Organization reported that in 2022, 1 in 8 people globally were living with obesity, further escalating the incidence of PAD. However, the high initial investment and limited accessibility in developing regions are the key challenging factors that are hampering the market growth during the estimated period of 2024-2032. The global obesity epidemic and the prevalence of diabetes significantly contribute to the rising cases of PAD, as both conditions are strongly associated with its development and progression. Unhealthy lifestyle habits like smoking and physical inactivity further exacerbate the risk, increasing the burden of PAD worldwide. The growing incidence of PAD has led to a heightened demand for effective treatment options, thereby driving market growth. Additionally, the aging population is expected to propel market growth. As individuals age, their risk of developing PAD increases significantly. According to a 2023 article by the Institute of Health Metrics and Evaluation, the global prevalence of PAD was higher among older adults. Aging causes structural and functional changes in blood vessels, including arterial stiffening, endothelial dysfunction, and the accumulation of atherosclerotic plaque, all contributing to PAD development and progression.
The rising prevalence of PAD among the elderly population underscores the urgent need for effective management strategies and healthcare interventions tailored to their unique needs. Healthcare providers and policymakers are increasingly recognizing the importance of early detection, comprehensive risk factor management, and timely intervention to minimize the impact of PAD on elderly individuals. Technological advancements in minimally invasive surgeries are expected to drive market growth. These surgeries offer less invasive alternatives to traditional open surgeries, resulting in reduced patient discomfort, shorter hospital stays, faster recovery times, and improved outcomes. The development of sophisticated catheter-based devices and techniques has expanded the range of minimally invasive treatment options for PAD. These include advanced angioplasty balloons, drug-coated balloons, atherectomy devices, and stents specifically designed for peripheral vascular interventions, offering greater flexibility, deliverability, and efficacy.
The key regions considered for the global EV Transmission System Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America accounted for a major share of the peripheral artery disease market in 2023, attributed to a well-developed healthcare infrastructure, the strong presence of major key players, and the rise in PAD prevalence. Whereas, Asia-Pacific is expected to register the highest CAGR during the forecast period due to the increasing geriatric population and developing healthcare infrastructure.
Major market players included in this report are:
- Philips N.V.
- Braun Melsungen AG
- Medtronic
- Bayer AG
- Boston Scientific Corporation
- Becton Dickinson and Company
- Terumo Medical Corporation
- Biotronik
- Cardinal Health
- Abbott
- Johnson & Johnson
- Cook Medical
- AngioDynamics
- Endologix
- Shockwave Medical
The detailed segments and sub-segment of the market are explained below:
By Product Type:
By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgery Centers
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Peripheral Artery Disease Market Executive Summary
- 1.1. Global Peripheral Artery Disease Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Product Type
- 1.3.2. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Peripheral Artery Disease Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Peripheral Artery Disease Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rise in prevalence of peripheral artery disease
- 3.1.2. Increase in geriatric population
- 3.1.3. Technological advancements in treatment devices
- 3.2. Market Challenges
- 3.2.1. High initial investment
- 3.2.2. Limited accessibility in developing regions
- 3.3. Market Opportunities
- 3.3.1. Growth in minimally invasive procedures
- 3.3.2. Expanding healthcare infrastructure in emerging markets
Chapter 4. Global Peripheral Artery Disease Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Peripheral Artery Disease Market Size & Forecasts by Product Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Peripheral Artery Disease Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Devices
- 5.2.2. Drugs
Chapter 6. Global Peripheral Artery Disease Market Size & Forecasts by End User 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Peripheral Artery Disease Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Hospitals
- 6.2.2. Specialty Clinics
- 6.2.3. Ambulatory Surgery Centers
Chapter 7. Global Peripheral Artery Disease Market Size & Forecasts by Region 2022-2032
- 7.1. North America Peripheral Artery Disease Market
- 7.1.1. U.S. Peripheral Artery Disease Market
- 7.1.1.1. Product Type breakdown size & forecasts, 2022-2032
- 7.1.1.2. End User breakdown size & forecasts, 2022-2032
- 7.1.2. Canada Peripheral Artery Disease Market
- 7.2. Europe Peripheral Artery Disease Market
- 7.2.1. UK Peripheral Artery Disease Market
- 7.2.2. Germany Peripheral Artery Disease Market
- 7.2.3. France Peripheral Artery Disease Market
- 7.2.4. Spain Peripheral Artery Disease Market
- 7.2.5. Italy Peripheral Artery Disease Market
- 7.2.6. Rest of Europe Peripheral Artery Disease Market
- 7.3. Asia-Pacific Peripheral Artery Disease Market
- 7.3.1. China Peripheral Artery Disease Market
- 7.3.2. India Peripheral Artery Disease Market
- 7.3.3. Japan Peripheral Artery Disease Market
- 7.3.4. Australia Peripheral Artery Disease Market
- 7.3.5. South Korea Peripheral Artery Disease Market
- 7.3.6. Rest of Asia Pacific Peripheral Artery Disease Market
- 7.4. Latin America Peripheral Artery Disease Market
- 7.4.1. Brazil Peripheral Artery Disease Market
- 7.4.2. Mexico Peripheral Artery Disease Market
- 7.4.3. Rest of Latin America Peripheral Artery Disease Market
- 7.5. Middle East & Africa Peripheral Artery Disease Market
- 7.5.1. Saudi Arabia Peripheral Artery Disease Market
- 7.5.2. South Africa Peripheral Artery Disease Market
- 7.5.3. Rest of Middle East & Africa Peripheral Artery Disease Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Philips N.V.
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. Braun Melsungen AG
- 8.3.3. Medtronic
- 8.3.4. Bayer AG
- 8.3.5. Boston Scientific Corporation
- 8.3.6. Becton Dickinson and Company
- 8.3.7. Terumo Medical Corporation
- 8.3.8. Biotronik
- 8.3.9. Cardinal Health
- 8.3.10. Abbott
- 8.3.11. Johnson & Johnson
- 8.3.12. Cook Medical
- 8.3.13. AngioDynamics
- 8.3.14. Endologix
- 8.3.15. Shockwave Medical
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
°ü·ÃÀÚ·á